07228nam 2202161z- 450 991055712910332120210501(CKB)5400000000040763(oapen)https://directory.doabooks.org/handle/20.500.12854/68429(oapen)doab68429(EXLCZ)99540000000004076320202105d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer AgentsDesign, Synthesis and EvaluationBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (606 p.)3-0365-0140-1 3-0365-0141-X This book is a printed edition of the Special Issue entitled "Anticancer Agents: Design, Synthesis and Evaluation" that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers.Anticancer AgentsMedicine and Nursingbicssc1,2,3-triazole2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide3,6-dibromocarbazole4-(pyridin-4-yloxy)benzamide5-bromoindole5-fluorouracilABCB1 (P-glycoprotein)actinADMEalleneamides/estersandrogen receptoranti-cancer activityanti-neuroinflammationanti-ovarian canceranti-tumoranticanceranticancer activityanticancer agentanticancer agentsanticancer compoundsantimitotic agentsantioxidant activityantiproliferative activityantiproliferative agentantitumorantitumor activityapalutamideapoptosisaromatasebenzimidazolebenzofuran-pyrazolebenzofuransbeta-lapachonebivalencybreast cancerc-Metcarbazolecell cyclechemical synthesischemoresistancechrysin analoguescolchiceinecolchicine amidecolchicine analogscolchicine sulfonamidecolon cancercomputational dockingcoumarincrystal structurecyanopyridonecytotoxic activitycytotoxic propertiescytotoxicitydarolutamideDFT studydihydroartemisinindihydropyranoindoledockingdocking studiesdrug discoverydrug resistanceE-stereoselectiveenzalutamideenzyme inhibitionestrone derivativesflavonoidflavonoidsgemcitabineHDAC inhibitorsHeLaHepG2hydrateshydrazineIGF-1RIL-12immune modulationindoleamine 2,3-dioxygenaseinflammationinhibitorK562kinase inhibitorMCF-7MDM2-p53 interactionmigrationmimeticsmolecular simulationMOLT-4multidrug resistance (MDR) reversalN-substituted pyrazolinenanoparticlesnatural productneuroblastomaNIH3T3o-nitro-benzylorganosilicon compoundsortho-quinonesovarian cancerovercoming drug resistanceP-glycoproteinP-MAPAPARP inhibitorPARP-1 inhibitionphenylpyrazolopyrimidinephotoactivatable protecting groupsPI3KsPI3Kα inhibitorPI3Kδ inhibitorspolyvalencyprodrugprostate cancerPROTACsprotein degradationprotein kinaseprotein-protein interactionsPyrazolepyrazolopyridinepyridotriazinequinazolin-4(3H)-onequinazolin-4(3H)-thioneregioselectivesalinomycinSchiff baseSILA-409 (Alis-409)SILA-421 (Alis-421)Srcsubstituted pyridinesynergysynthesisTalazoparibtanshione IIAtaxoidsthiazolidinoneThienopyrimidinethienopyrimidinonethiocolchicinethiopenethioxotriazopyridineTLR signalingtopoisomerase II inhibitortriazolothiadiazinetriple-negative breast cancertryptophan metabolismtubulin inhibitorstumor specificityureavirtual screeningxanthonesyeast-based assayszampanolideβIII-tubulinMedicine and NursingChen Qiao-Hongedt1313308Chen Qiao-HongothBOOK9910557129103321Anticancer Agents3031264UNINA